The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus.
Non-dysplastic mucosa (ND-) in Barrett's esophagus (BE) shows clonal molecular aberrations, loss of cell cycle control, and other features of "neoplasia." These changes occur prior to morphologic expression of neoplasia (dysplasia). Morphologic evaluation of dysplasia is fraught with error, and, as a result, often leads to false-negative and false-positive diagnoses. Early "crypt dysplasia" is difficult to detect, and is often missed in routine biopsy specimens. Some studies show substantial progression rates of low-grade dysplasia (LGD), and crypt dysplasia, to esophageal adenocarcinoma (EAC). Dysplasia, even when fully developed, may, in certain circumstances, be difficult to differentiate from non-dysplastic (regenerating) BE. Radiofrequency ablation (RFA) is a safe and effective method for removing mucosa at risk of cancer. Given the difficulties of dysplasia assessment in mucosal biopsies, and the molecular characteristics of ND-BE, this technique should be considered for treatment of all BE patients, including those with ND or LGD. Post-ablation neo-squamous epithelium reveals no molecular abnormalities, and is biologically stable. Given that prospective randomized controlled trials of ablative therapy for ND-BE aiming at reducing EAC incidence and mortality are unlikely to be completed in the near future, endoscopic ablation is a valid management option. The success of RFA in achieving safe, uniform, reliable, and predictable elimination of BE allows surgeons to combine fundoplication with RFA. Currently, there is no type of treatment for dysplastic or non-dysplastic BE that achieves a complete response in 100% of patients, eliminates all risk of developing cancer, results in zero adverse events, is less expensive in terms of absolute costs than surveillance, is durable for 20+ years, or eliminates the need for surveillance. Regardless, RFA shows established safety, efficacy, durability, and cost-effective profiles that should be considered in the management of patients with non-dysplastic or low-grade dysplastic BE.
Fleischer
David E
DE
Department of Internal Medicine, Mayo Clinic in Arizona, Scottsdale, AZ 85259, USA. fleischer.david@mayo.edu
Odze
Robert
R
Overholt
Bergein F
BF
Carroll
John
J
Chang
Kenneth J
KJ
Das
Ananya
A
Goldblum
John
J
Miller
Daniel
D
Lightdale
Charles J
CJ
Peters
Jeffrey
J
Rothstein
Richard
R
Sharma
Virender K
VK
Smith
Daniel
D
Velanovich
Victor
V
Wolfsen
Herbert
H
Triadafilopoulos
George
G
D000230:Adenocarcinoma / Q000473:pathology / Q000517:prevention & control / Q000601:surgery; D001471:Barrett Esophagus / Q000473:pathology* / Q000601:surgery*; D001707:Biopsy, Needle; D017115:Catheter Ablation / Q000379:methods*; D004724:Endoscopy / Q000379:methods; D004938:Esophageal Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000601:surgery; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D011230:Precancerous Conditions / Q000473:pathology* / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016896:Treatment Outcome
Surg Oncol Clin N Am. 2009 Jul;18(3):453-67
19500736
Cancer Res. 2004 Oct 15;64(20):7629-33
15492292
Keio J Med. 2009 Mar;58(1):12-8
19398879
Cancer. 1998 Aug 15;83(4):652-9
9708927
Cancer Prev Res (Phila). 2008 Nov;1(6):413-23
19138988
Hum Pathol. 1999 Apr;30(4):412-8
10208462
Am J Gastroenterol. 2009 Feb;104(2):502-13
19174812
Am J Gastroenterol. 2009 Jun;104(6):1356-62
19491849
Ann Thorac Surg. 1998 Dec;66(6):1886-93
9930464
Am J Gastroenterol. 2009 Apr;104(4):816-24
19293780
Arch Pathol Lab Med. 2008 Oct;132(10):1577-85
18834215
Gastroenterology. 1978 Oct;75(4):683-7
710836
Am J Gastroenterol. 1997 Feb;92(2):222-5
9040195
Gastroenterology. 1992 Dec;103(6):1769-76
1360434
Aliment Pharmacol Ther. 2006 Mar 15;23(6):727-33
16556174
Hum Pathol. 1994 Oct;25(10):982-93
7927321
Aliment Pharmacol Ther. 2010 Feb 1;31(3):440-51
19843025
Dis Esophagus. 2007;20(6):497-503
17958725
Cancer Res. 2000 Sep 15;60(18):5021-6
11016622
Am J Physiol Gastrointest Liver Physiol. 2000 Jun;278(6):G1000-9
10859231
Ann Intern Med. 2003 Feb 4;138(3):176-86
12558356
J Clin Invest. 1996 Nov 1;98(9):2120-8
8903332
Gastroenterology. 2002 Mar;122(3):633-40
11874995
J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95
10601379
Gastrointest Endosc. 2010 Jan;71(1):147-66
19879565
J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21
10944553
Surg Endosc. 2006 Feb;20(2):226-9
16362470
Am J Gastroenterol. 1999 Aug;94(8):2043-53
10445526
Am J Surg Pathol. 2008 Sep;32(9):1327-35
18670357
Gastroenterology. 2000 Mar;118(3):487-96
10702199
Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005
16573802
Am J Gastroenterol. 1988 Mar;83(3):291-4
3125739
N Engl J Med. 2009 Dec 24;361(26):2548-56
20032324
Gastrointest Endosc. 2005 Oct;62(4):488-98
16185958
Int J Cancer. 2006 Aug 15;119(4):765-70
16550596
Am J Gastroenterol. 2008 Mar;103(3):788-97
18341497
J Surg Oncol. 2005 Dec 1;92(3):169-90
16299787
J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11
11078757
Clin Gastroenterol Hepatol. 2009 Jun;7(6):613-23
19281858
Clin Gastroenterol Hepatol. 2010 Jan;8(1):7-9
19788932
Am J Gastroenterol. 2009 Oct;104(10):2588-94
19623166
Clin Gastroenterol Hepatol. 2003 Jul;1(4):258-63
15017666
J Thorac Cardiovasc Surg. 2010 Mar;139(3):713-6
20074750
Gut. 2005 Aug;54(8):1062-6
15857935
Clin Gastroenterol Hepatol. 2006 May;4(5):566-72
16630761
Cell. 2000 Jan 7;100(1):57-70
10647931
Genes Chromosomes Cancer. 2007 Jun;46(6):532-42
17330261
Cancer Res. 1994 May 1;54(9):2292-5
8162566
Aliment Pharmacol Ther. 2001 Mar;15(3):269-76
11207503
N Engl J Med. 2009 May 28;360(22):2277-88
19474425
Lab Invest. 2007 May;87(5):466-72
17310216
Am J Gastroenterol. 2001 Nov;96(11):3071-83
11721752
Cancer Res. 2001 Nov 15;61(22):8284-9
11719461